Ensign Peak Advisors
PMVP icon

Ensign Peak Advisors’s PMV Pharmaceuticals PMVP Stock Holding History

Ensign Peak Advisors’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-34,718
Closed -$413K – 2108
2022
Q3 		$413K Buy
34,718
+2,190
+7% +$31.6K ﹤0.01% 1556
2022
Q2 		$464K Buy
32,528
+32,188
+9,467% +$468K ﹤0.01% 1497
2022
Q1 		$7K Hold
340
– – ﹤0.01% 2198
2021
Q4 		$8K Buy
+340
New +$8.21K ﹤0.01% 2190

Other funds holding PMVP

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Ensign Peak Advisors's PMVP Position: Q4 2022 in Review

Ensign Peak Advisors sold out of PMV Pharmaceuticals (PMVP) in Q4 2022, closing a stake of 34,718 shares — an estimated $413K sold.

Ensign Peak Advisors first reported a position in PMVP in Q4 2021 and held it in 4 quarters. The position peaked at $464K in Q2 2022. 115 funds tracked by Wall St. Rank hold PMVP as of Q4 2022.

  • Ensign Peak Advisors reported no remaining PMV Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 34,718 PMV Pharmaceuticals shares in Q4 2022, an estimated $413K.
  • Ensign Peak Advisors first reported a position in PMV Pharmaceuticals in Q4 2021 and held it in 4 quarters.
  • Ensign Peak Advisors's PMV Pharmaceuticals position peaked at $464K in Q2 2022.
  • 115 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q4 2022.

Based on Ensign Peak Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.